急性缺血性卒中的神经保护治疗
文章指出急性缺血性卒中的「再灌注革命」时代正走向终结:药物与机械血流恢复疗法日益有效,当前血管内取栓可开通超过85%的闭塞动脉,进一步提升空间有限。然而单纯成功再灌注仅部分解决治疗难题:大血管闭塞所致缺血性卒中接受取栓的患者中,逾三分之二最终结局仍为残疾。原因在于再通前已累积不可逆损伤,再灌注本身又产生额外损伤。为完全消除卒中相关残疾,需要互补治疗:桥接神经保护剂使脑细胞耐受缺血直至再灌注、再灌注神经保护剂避免再灌注损伤、神经修复剂促进损伤后神经元与突触重组。
要点
- 当前血管内取栓再通超过85%的闭塞动脉,再灌注策略进一步提升空间有限。
- 大血管闭塞缺血性卒中接受取栓者中,逾三分之二最终结局仍为残疾。
- 再通前已累积不可逆损伤、再灌注本身又产生额外损伤,是再灌注不能完全恢复的原因。
- 需互补治疗:桥接神经保护剂、再灌注神经保护剂、神经修复剂三类。
适用人群与场景
- 急性缺血性卒中患者,尤其大血管闭塞并接受血管内取栓者。
研究设计与关键结果
- 当前血管内取栓方法可开通超过85%的闭塞动脉。
- 大血管闭塞所致缺血性卒中接受血管内取栓的患者中,逾三分之二最终结局为残疾。
- 再灌注不能完全恢复的原因包括再通前已累积的不可逆损伤与再灌注本身产生的额外损伤。
- 作者提出互补治疗包括桥接神经保护剂、再灌注神经保护剂与神经修复剂。
证据类型、等级与局限
- 证据类型:综述(作者述评)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,要完全消除卒中相关残疾,需在再灌注基础上加用桥接神经保护剂、再灌注神经保护剂与神经修复剂等互补治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
A remarkable era in acute ischemic stroke care is now coming to a close—the period of the “reperfusion revolution.” Over the past few decades, pharmacological and mechanical flow restoration therapies became steadily more effective. By restoring blood flow and terminating the ischemic period, reperfusion salvages those cerebral tissues not yet irreversibly injured. However, the reperfusion strategy in acute stroke care is now reaching its limits. Current endovascular thrombectomy approaches reopen over 85% of occluded arteries, leaving little scope for further advance. And successful reperfusion treatment alone clearly only partially solves the therapeutic challenge. Among patients with ischemic stroke due to large-vessel occlusion who receive endovascular thrombectomy, more than two-thirds nevertheless have a disabled final outcome. Restoring blood flow yields incomplete recoveries because some irreversible injury accrues before recanalization can be achieved and additional injury is generated by reperfusion itself. To fully eradicate stroke-related disability, complementary therapies are needed, including: bridging neuroprotection agents, which allow brain cells to tolerate ischemia until reperfusion is attained; reperfusion neuroprotection agents, which avert reperfusion injury; and neuroreparative agents, which promote postinjury reorganization of neurons and synapses.
参考来源
- JAMA(当期):Neuroprotective Therapy for Acute Ischemic Stroke
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。